Nikita Shah's most recent trade in Amneal Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 188,356 Performance-Based Restricted Stock Units done . Disclosure was reported to the exchange on March 3, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 188,356 | 188,356 | - | - | Performance-Based Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 144,928 | 0 | - | - | Performance-Based Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 144,928 | 494,674 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 94,178 | 94,178 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 74,131 | 420,543 (0%) | 0% | 8.8 | 649,388 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 45,872 | 91,743 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 45,872 | 373,210 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 36,232 | 36,232 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 36,232 | 345,871 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 35,879 | 456,422 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 35,879 | 107,640 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 23,464 | 349,746 (0%) | 0% | 8.8 | 205,545 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 18,533 | 327,338 (0%) | 0% | 8.8 | 162,349 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.84 per share. | 03 Mar 2025 | 18,353 | 438,069 (0%) | 0% | 8.8 | 162,241 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 28,958 | 320,624 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 28,958 | 0 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.67 per share. | 01 Mar 2025 | 10,985 | 309,639 (0%) | 0% | 8.7 | 95,240 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 14 Aug 2024 | 100,000 | 291,666 (0%) | 0% | 7.8 | 775,000 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 287,038 | 287,038 | - | - | Performance-Based Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 143,519 | 143,519 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 45,871 | 137,615 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 45,871 | 414,648 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 36,232 | 72,464 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 36,232 | 386,930 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 28,957 | 365,879 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 28,957 | 28,958 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 01 Mar 2024 | 22,982 | 391,666 (0%) | 0% | 5.5 | 125,712 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 01 Mar 2024 | 18,153 | 368,777 (0%) | 0% | 5.5 | 99,297 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 01 Mar 2024 | 15,181 | 350,698 (0%) | 0% | 5.5 | 83,040 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 35,620 | 0 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 35,620 | 355,592 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.71 per share. | 27 Feb 2024 | 18,670 | 336,922 (0%) | 0% | 5.7 | 106,606 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 366,972 | 366,972 | - | - | Performance-Based Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 183,486 | 183,486 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 36,232 | 338,036 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 36,232 | 108,696 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.92 per share. | 03 Mar 2023 | 18,064 | 319,972 (0%) | 0% | 1.9 | 34,683 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 28,958 | 317,359 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 28,958 | 57,915 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 01 Mar 2023 | 15,555 | 301,804 (0%) | 0% | 2.1 | 32,510 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 11,729 | 294,905 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 11,729 | 0 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 01 Mar 2023 | 6,504 | 288,401 (0%) | 0% | 2.1 | 13,593 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 35,620 | 302,928 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 35,620 | 35,620 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.16 per share. | 27 Feb 2023 | 19,752 | 283,176 (0%) | 0% | 2.2 | 42,664 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2022 | 4,442 | 0 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2022 | 4,442 | 269,536 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 07 May 2022 | 2,228 | 267,308 (0%) | 0% | 3.4 | 7,575 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 289,856 | 289,856 | - | - | Performance-Based Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 144,928 | 144,928 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 28,957 | 86,873 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 28,957 | 273,999 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 11,728 | 11,729 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 11,728 | 248,649 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.45 per share. | 01 Mar 2022 | 8,905 | 265,094 (0%) | 0% | 4.4 | 39,627 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.45 per share. | 01 Mar 2022 | 3,607 | 245,042 (0%) | 0% | 4.4 | 16,051 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2022 | 35,620 | 71,240 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2022 | 35,620 | 248,616 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.59 per share. | 27 Feb 2022 | 11,695 | 236,921 (0%) | 0% | 4.6 | 53,680 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 15 Dec 2021 | 2,000 | 212,996 (0%) | 0% | 4.0 | 7,900 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 4,441 | 4,442 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 4,441 | 216,362 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.20 per share. | 07 May 2021 | 1,366 | 214,996 (0%) | 0% | 5.2 | 7,103 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.75 per share. | 15 Mar 2021 | 36,330 | 248,251 (0%) | 0% | 2.8 | 99,908 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 36,330 | 36,331 | - | - | Stock Option (Right to Buy) | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Sale of securities on an exchange or to another person at price $ 6.87 per share. | 15 Mar 2021 | 36,330 | 211,921 (0%) | 0% | 6.9 | 249,489 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 231,660 | 231,660 | - | - | Performance-Based Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 115,830 | 115,830 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 35,620 | 215,347 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 35,620 | 106,860 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 11,729 | 215,528 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 11,729 | 23,457 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.39 per share. | 27 Feb 2021 | 11,548 | 203,799 (0%) | 0% | 5.4 | 62,244 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.18 per share. | 27 Feb 2021 | 3,607 | 211,921 (0%) | 0% | 5.2 | 18,684 | Class A Common Stock |
Amneal Pharmaceuticals Inc... | Nikita Shah | SVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2020 | 4,442 | 8,883 | - | - | Restricted Stock Units | |
Amneal Pharmaceuticals Inc... | Nikita Shah | SVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2020 | 4,442 | 181,053 (0%) | 0% | - | Class A Common Stock | |
Amneal Pharmaceuticals Inc... | Nikita Shah | SVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 07 May 2020 | 1,326 | 179,727 (0%) | 0% | 3.5 | 4,707 | Class A Common Stock |